Physician profile
Guy R Ulrich
NPI 1720084056
$5,422.77
in general payments reported to CMS, 2019-2025
35 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,932 · 2020: $1,658 · 2021: $159 · 2022: $152 · 2023: $131 · 2024: $91.95 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.87 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,226.23 | 2019-2023 | Evenity |
| Novartis Pharmaceuticals Corporation | $530.60 | 2019-2020 | |
| Pfizer INC. | $529.75 | 2019-2023 | |
| Novo Nordisk INC | $431.02 | 2019-2020 | |
| Amarin Pharma, INC. | $281.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.84 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $262.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $201.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $194.28 | 2019-2022 | |
| Astellas Pharma US INC | $190.88 | 2019-2021 | |
| Daiichi Sankyo INC. | $190.48 | 2019-2020 | |
| Edwards Lifesciences Corporation | $158.52 | 2021-2024 | Sapien 3 Ultra Resilia |
| Atricure, INC. | $156.65 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Lilly USA, LLC | $135.78 | 2019-2020 | |
| Abbvie INC. | $123.76 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $68.33 | 2020-2021 | |
| Sanofi Pasteur INC. | $54.40 | 2019 | |
| Eisai INC. | $50.08 | 2020 | |
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.58 | 2019 | |
| Seqirus USA INC | $36.32 | 2019-2020 | |
| Bioventus LLC | $24.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.82 | 2019 | |
| Vivus LLC | $21.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.61 | 2019 | |
| Allergan, INC. | $19.30 | 2020 | |
| Abbott Laboratories | $19.25 | 2020 | |
| Vertiflex, INC. | $19.19 | 2019 | |
| Esperion Therapeutics, INC. | $19.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.63 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.45 | 2019 | |
| Genentech USA, INC. | $15.30 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.